Gysembergh A, Simkhovich B Z, Kloner R A, Przyklenk K
Heart Institute, Good Samaritan Hospital and Department of Medicine, University of California, Los Angeles, CA 90017-2395, USA.
J Mol Cell Cardiol. 2001 Apr;33(4):681-90. doi: 10.1006/jmcc.2000.1331.
Our aim was to test the hypothesis that cardioprotection achieved with ischemic preconditioning (PC) involves increased activity of p38 mitogen-activated protein kinase (MAPK) early during sustained coronary artery occlusion. Using the isolated buffer-perfused rabbit heart model of regional ischemia, we quantified p38 MAPK activity (pmol/min/mg protein: by biochemical assay) at 5 and 10 min into coronary occlusion in hearts that first received PC ischemia or no intervention (controls), and in non-ischemic shams. Control hearts exhibited significant increases in p38 MAPK activity, averaging 883+/-142 and 1135+/-179 at 5 and 10 min of occlusion, v 144+/-49 in shams (P<0.05 and P<0.01). p38 MAPK activity was not, however, augmented with PC; rather, at 5 min into occlusion, activity was attenuated, averaging 432+/-72 (P=N.S. v sham). This early, modest reduction in p38 MAPK activity may be physiologically relevant: in additional hearts subjected to 30 min of sustained coronary occlusion and 2 h of reperfusion, infarct size (by tetrazolium staining: expressed as a % of the risk region) was 54+/-5% in hearts treated with SB 203580 (confirmed in our study to inhibit p38 MAPK activity at 5 min into occlusion) v 70+/-5% in vehicle controls (P<0.05). Thus, cardioprotection achieved with ischemic preconditioning in rabbit heart does not involve augmentation of p38 MAPK activity early during sustained coronary occlusion.
缺血预处理(PC)实现的心脏保护作用涉及在冠状动脉持续闭塞早期p38丝裂原活化蛋白激酶(MAPK)活性增加。使用离体缓冲液灌注兔心脏局部缺血模型,我们在首次接受PC缺血或未干预(对照)的心脏以及非缺血假手术组心脏中,于冠状动脉闭塞5分钟和10分钟时,通过生化测定法对p38 MAPK活性(pmol/分钟/毫克蛋白)进行了定量。对照心脏的p38 MAPK活性显著增加,在闭塞5分钟和10分钟时平均分别为883±142和1135±179,而假手术组为144±49(P<0.05和P<0.01)。然而,PC并未增强p38 MAPK活性;相反,在闭塞5分钟时,活性减弱,平均为432±72(P=无显著性差异 对比假手术组)。p38 MAPK活性的这种早期适度降低可能具有生理相关性:在另外一些经历30分钟冠状动脉持续闭塞和2小时再灌注的心脏中,用SB 203580处理的心脏(在我们的研究中证实其在闭塞5分钟时可抑制p38 MAPK活性)梗死面积(通过四氮唑染色:表示为危险区域的百分比)为54±5%,而载体对照组为70±5%(P<0.05)。因此,兔心脏缺血预处理实现的心脏保护作用并不涉及在冠状动脉持续闭塞早期增强p38 MAPK活性。